We are live on ! Find out more
BB

BB Biotech Portfolio holdings

AUM $3.98B
1-Year Est. Return 15.47%
This Fund
S&P 500
This Quarter Est. Return
+10.99%
1 Year Est. Return
+15.47%
3 Year Est. Return
+121.5%
5 Year Est. Return
+265.65%
10 Year Est. Return
–
AUM
$3.61B
AUM Growth
+$341M
Cap. Flow
+$76.3M
Cap. Flow %
2.11%
Top 10 Hldgs %
74.41%
Holding
28
New
–
Increased
15
Reduced
4
Closed
1

Top Buys

Rank Stock Value
1
ESPR
Esperion Therapeutics
ESPR
+$28.2M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$26.6M
3
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$24.8M
4
INCY icon
Incyte
INCY
+$19.4M
5
RDUS
Radius Health, Inc.
RDUS
+$18.1M

Top Sells

Rank Stock Value
1
KITE
Kite Pharma, Inc.
KITE
+$66.3M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$9.39M
3
CELG
Celgene Corp
CELG
+$8.85M
4
AGIO icon
Agios Pharmaceuticals
AGIO
+$7.18M
5
JUNO
Juno Therapeutics, Inc.
JUNO
+$4.43M

Sector Composition

Rank Sector Weight
1 Healthcare 91.58%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NVAX icon
26
Novavax
NVAX
$1.31B
$9.5M 0.26%
416,500
– –
ACHN
27
DELISTED
Achillion Pharmaceuticals
ACHN
$5.74M 0.16%
1,279,340
– –
KITE
28
DELISTED
Kite Pharma, Inc.
KITE
– –
-640,000
Closed -$66.3M
1
2

Similar funds

SBAM
Santa Barbara Asset Management Los Angeles, California $6.43B AUM 10.99% 1-Year Est. Return
HFS
HL Financial Services Louisville, Kentucky $6.5B AUM 10.02% 1-Year Est. Return
SA
SQ Advisors Naples, Florida $1.32B AUM 10.3% 1-Year Est. Return
WF
WealthTrust Fairport Cleveland, Ohio $1.06B AUM 3.47% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
AB
AT Bancorp Dubuque, Iowa $823M AUM 17.19% 1-Year Est. Return
MFBTD
MB Financial Bank - Trust Department Rosemont, Illinois $816M AUM 5.49% 1-Year Est. Return

BB Biotech's Q3 2017 Portfolio in Review

As of Q3 2017, BB Biotech held 28 positions worth $3.61B, up 10% from $3.27B the previous quarter. Its ten largest holdings account for 74% of the portfolio.

Trading was light in Q3 2017: portfolio turnover was 3.6%. BB Biotech opened no new positions and exited 1, leaving the 28-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 89% a quarter earlier.

  • BB Biotech added most to Esperion Therapeutics in Q3 2017, an estimated $28.2M increase.
  • BB Biotech's biggest Q3 2017 reduction was Alnylam Pharmaceuticals, cutting an estimated $9.39M.
  • BB Biotech fully exited Kite Pharma, Inc. in Q3 2017, selling an estimated $66.3M.
  • BB Biotech's ten largest holdings make up 74% of its $3.61B portfolio in Q3 2017.
  • BB Biotech opened 0 new positions and closed 1 in Q3 2017.
  • BB Biotech's portfolio value rose 10% quarter-over-quarter to $3.61B.

Based on BB Biotech's 13F filing for Q3 2017, filed 13 Nov 2017.